Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-4139 tablets and will conduct clinical trials in the near future.

HRS-4139 tablets are a class 1 new drug independently developed by the company. In animal models, they can effectively improve psoriatic symptoms and inhibit inflammatory response. According to inquiries, no drugs with the same target have been approved for marketing at home or abroad. Up to now, the total R&D investment for HRS-4139 film-related projects is about 20.4 million yuan (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.